Skip to Main Content

Cell and gene therapy companies are opening the door to a paradigm shift in medicine as they rapidly develop effective new therapies and change patients’ lives for the better. They are also carving out a unique path in life sciences leadership.

As a result of their rapid growth, cell and gene therapy (C&GT) companies face a distinct set of challenges — from manufacturing and pricing to supply chain transportation and product security — that sets them apart from the rest of the biopharma sector. They’re subject to the pressures of delivering complex innovations in very short time frames, putting company leaders under high pressure from day one. That means management teams must be built faster and be more broadly based than in purely R&D-focused drug discovery enterprises.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!